Johnson & Johnson's Q1 2021 earnings call showed strong performance across segments, exceeding expectations in medical devices and pharmaceuticals.  Management highlighted continued growth driven by volume, not price increases, and robust R&D investments.  While the company faces some challenges regarding the COVID-19 vaccine and potential future regulatory pressures, the overall positive outlook and increased guidance suggests a likely positive short-term impact on the stock price due to the strength of their key segments and confidence in the future.
[1]
